日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Durvalumab Plus Chemotherapy in Patients With EGFR-Mutated Advanced NSCLC Whose Disease Progressed on First-Line Osimertinib: ORCHARD

Durvalumab联合化疗治疗一线奥希替尼治疗后疾病进展的EGFR突变晚期非小细胞肺癌患者:ORCHARD

Cho, Byoung Chul; Nishio, Makoto; Ahn, Myung-Ju; García-Campelo, Rosario; Ponce, Santiago; Baik, Christina; Salgia, Ravi; Kim, Sang-We; Lee, Jong Seok; Yoshida, Tatsuya; Yu, Helena A; Goldberg, Sarah B; Johannes de Langen, Adrianus; Le, Xiuning; Piotrowska, Zofia; Riess, Jonathan W; Tanaka, Kentaro; Ambrose, Helen; Cosaert, Jan; Fraenkel, Paula G; Tang, Kwan Ho; Lehman, Jonathan M; Smith, Paul; Goldman, Jonathan W

Hydroxychloroquine prevents resistance and potentiates the antitumor effect of SHP2 inhibition in NF1-associated malignant peripheral nerve sheath tumors.

羟氯喹可防止耐药性,并增强 SHP2 抑制剂对 NF1 相关恶性周围神经鞘瘤的抗肿瘤作用

Sait Sameer Farouk, Tang Kwan Ho, Angus Steven P, Brown Rebecca, Sun Daochun, Xie Xuanhua, Iltis Charlene, Lien Michelle, D Socci Nicholas, Bale Tejus A, Davis Christopher, Dixon Shelley A H, Zhang Chi, Wade Clapp D, Neel Benjamin G, Parada Luis F

Cellular adaptation to cancer therapy along a resistance continuum.

细胞对癌症治疗的适应性沿着耐药性连续谱发展

França Gustavo S, Baron Maayan, King Benjamin R, Bossowski Jozef P, Bjornberg Alicia, Pour Maayan, Rao Anjali, Patel Ayushi S, Misirlioglu Selim, Barkley Dalia, Tang Kwan Ho, Dolgalev Igor, Liberman Deborah A, Avital Gal, Kuperwaser Felicia, Chiodin Marta, Levine Douglas A, Papagiannakopoulos Thales, Marusyk Andriy, Lionnet Timothée, Yanai Itai

SHP2 Inhibition Prevents Adaptive Resistance to MEK Inhibitors in Multiple Cancer Models.

SHP2 抑制可防止多种癌症模型中对 MEK 抑制剂产生适应性耐药性

Fedele Carmine, Ran Hao, Diskin Brian, Wei Wei, Jen Jayu, Geer Mitchell J, Araki Kiyomi, Ozerdem Ugur, Simeone Diane M, Miller George, Neel Benjamin G, Tang Kwan Ho